Valuation : Autolus Therapeutics plc

Market Cap 60Cr 51Cr 48Cr 44Cr 82Cr 5.64TCr 83Cr 569.46Cr 221.77Cr 2.88TCr 223.89Cr 219Cr 9.28TCr P/E 2026 *
-2.78x
P/E 2027 * -3.28x
Enterprise Value 44Cr 38Cr 36Cr 33Cr 61Cr 4.16TCr 61Cr 420.43Cr 163.73Cr 2.13TCr 165.29Cr 161.69Cr 6.85TCr EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week-3.39%
Current month-2.98%
1 month+25.27%
3 months+40.74%
6 months+40.74%
Current year+14.57%
1 week 2.22
Extreme 2.22
2.38
1 month 1.8
Extreme 1.8
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

Chief Executive Officer

69,17,877 4.1641%
18/03/26 Other

Chairman

2,80,000 0.1685%
Change 5-day change 1-year change 3-year change Capi.($)
+2.23%-3.39%+58.33%-27.39% 60Cr
-1.00%+4.28%+49.39%+2.35% 8.51TCr
-2.49%+3.18%+512.54%+34.71% 6.02TCr
+0.95%+1.77%-15.77%-34.78% 5.97TCr
-1.60%-7.63%-3.65%+31.05% 5.11TCr
+0.09%-0.14%+11.61%+165.71% 4.87TCr
+0.83%+1.20%+58.28%-15.82% 3.29TCr
-0.62%+0.13%+47.09%+102.13% 2.61TCr
+0.79%-6.56%-2.56%+192.31% 2.26TCr
+1.10%-1.67%+64.17%+113.16% 1.64TCr
Average -0.06%-1.65%+77.94%+56.34% 4.03TCr
Weighted average by Cap. -0.56%-0.79%+95.86%+45.13%

Financials

2026 *2027 *
Net sales 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 143.06Cr 56Cr 723.58Cr 56Cr 55Cr 2.33TCr 19Cr 17Cr 16Cr 14Cr 27Cr 1.82TCr 27Cr 183.79Cr 72Cr 929.56Cr 72Cr 71Cr 2.99TCr
Net income -22Cr -19Cr -18Cr -16Cr -30Cr -2.07TCr -30Cr -209.03Cr -81Cr -1.06TCr -82Cr -80Cr -3.4TCr -19Cr -16Cr -15Cr -14Cr -26Cr -1.75TCr -26Cr -177.09Cr -69Cr -895.67Cr -70Cr -68Cr -2.88TCr
Net Debt -16Cr -13Cr -13Cr -12Cr -22Cr -1.47TCr -22Cr -149.03Cr -58Cr -753.76Cr -59Cr -57Cr -2.43TCr -7.74Cr -6.66Cr -6.25Cr -5.72Cr -11Cr -731.46Cr -11Cr -74Cr -29Cr -373.8Cr -29Cr -28Cr -1.2TCr
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
04/26/04 $2.280 +1.79% 13,32,632
02/26/02 $2.240 -3.03% 23,07,870
01/26/01 $2.310 -1.70% 14,77,729
31/26/31 $2.350 +0.43% 11,97,017
28/26/28 $2.340 -0.85% 14,36,887
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.240USD
Average target price
8.725USD
Spread / Average Target
+289.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock